Peripheral Neuropathy and Platelet-rich plasma (PRP): what the trial registry contains
The ClinicalTrials.gov registry holds 24 records for PRP in Peripheral Neuropathy: 1 recruiting now, 4 labelled Phase 3 or 4, across 5 countries. Snapshot 2026-08-29.
Why this is studied in Peripheral Neuropathy
Peripheral neuropathy covers diabetic, chemotherapy-induced and idiopathic nerve damage with very different prognoses. Cell rationales target microvascular support and nerve regeneration, and unlike the central nervous system, peripheral nerves do regenerate — slowly, and only if the underlying cause is controlled.
What PRP means in this table
Platelet-rich plasma is a blood product, not a stem-cell product, though it is routinely sold as part of the same package. Preparation varies enormously between systems — platelet concentration, leukocyte content and activation all differ — so the label describes a category of procedure rather than a defined substance, which is the main reason its trial literature is so inconsistent.
The numbers
Every figure below comes from one reproducible query (peripheral neuropathy x platelet-rich plasma) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 24 |
| Interventional studies in the sample | 23 |
| Recruiting right now | 1 |
| Completed | 13 |
| Terminated, withdrawn or suspended | 1 |
| Phase 3 or Phase 4 records | 4 |
| Countries with at least one site | 5 |
| Median planned enrolment | 60 participants |
| Largest single planned enrolment | 90 participants |
| First / most recent start year | 2012 — 2025 |
How mature is this evidence?
The ladder is partly climbed: 4 confirmatory-phase records against 24 in total, with the remainder concentrated in dose-finding and safety territory.
Registrations do not all survive contact with recruitment — 13 completed here, 1 stopped early, giving a 4% attrition rate.
| Phase label | Records | Share |
|---|---|---|
| Not applicable | 16 | 64% |
| Phase 1 | 3 | 12% |
| Phase 3 | 2 | 8% |
| Phase 4 | 2 | 8% |
| Phase 2 | 2 | 8% |
Median planned enrolment is 60 participants (largest single study: 90). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Across 5 countries with registered sites, Egypt dominates at roughly 52% — a concentration driven by funding and regulation rather than by clinical outcome.
| Country | Studies with a site there |
|---|---|
| Egypt | 11 |
| Taiwan | 6 |
| Turkey (Türkiye) | 2 |
| Spain | 1 |
| United States | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
The sponsor mix is academic (11 academic or hospital, 1 commercial among the most frequent lead sponsors).
- Tri-Service General Hospital (TSGH) — 5 records
- Assiut University — 3 records
- Taipei Medical University Hospital — 1 record
- Dalia Salah Saif — 1 record
- Baskent University — 1 record
- Saint Bernard Mission University — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07565844 — Intradermal Exosomes, Platelet-Rich Plasma, and Steroids for Post-Herpetic Neuralgia | n/a | Recruiting | 45 | Zagazig University | 2025-02-02 |
| NCT06249503 — Ultrasound Guided Activated and Non Activated Platelet Rich Plasma Injection Versus Hydro Dissection by Steroids. | Phase 4 | Completed | 90 | Ain Shams University | 2023-02-01 |
| NCT06209957 — Study of Single Platelet-Rich Plasma Local Injection Vs. Single Corticosteroid Local Injection in Carpal Tunnel Syndrome | Phase 4 | Completed | 40 | Menoufia University | 2017-06-01 |
| NCT04434105 — Ultrasound-guided PRP Versus Steroid Injections in Management of Carpal Tunnel Syndrome | Phase 2, Phase 3 | Unknown | 90 | Tanta University | 2020-02-01 |
| NCT04000932 — Platelet Rich Plasma in Carpal Tunnel Syndrome | Phase 3 | Unknown | 84 | Baskent University | 2018-07-15 |
| NCT05348408 — Efficacy of Peri-neural Platelet Rich Plasma Injection in Treatment of Chemotherapy Induced Peripheral Neuropathy | Phase 2 | Completed | 62 | South Egypt Cancer Institute | 2022-04-01 |
| NCT04235426 — Platelet Rich Plasma Injection Versus Surgical and Medical Treatment of Mild-moderate Carpel Tunnel Syndrome. | Phase 1 | Unknown | 90 | Dalia Salah Saif | 2018-01-26 |
| NCT05053477 — Radiofrequency, Perineural Injection, Idiopathic Carpal Tunnel Syndrome | Phase 1 | Unknown | 75 | Alexandria University | 2018-09-01 |
| NCT02993809 — Autologous Transplantation of BM-ECs With Platelet-Rich Plasma Extract for the Treatment of Critical Limb Ischemia | Phase 1 | Unknown | 40 | South China Research Center for Stem Cell and Regenerative M | 2018-03 |
| NCT06638008 — Ultrasound Guided Placental Growth Factor Vs Platelet Rich Plasma Injection in Peripheral Nerve Injury: an Interventional Study | n/a | Not Yet Recruiting | 75 | Assiut University | 2025-01-15 |
What this page does and does not tell you
A registry is a plan repository. Counting entries tells you what people intended to study, which is a weaker thing than what they found.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many PRP studies for Peripheral Neuropathy are recruiting right now?
1 of 24 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is PRP an approved treatment for Peripheral Neuropathy?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 24 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on PRP for Peripheral Neuropathy?
4 of 24 records carry a Phase 3 or Phase 4 label and 13 are marked completed. Registrations run from 2012 to 2025.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Peripheral Neuropathy: cell-therapy evidence and registered trials
- How much does stem cell therapy for Peripheral Neuropathy cost? (2026)
- Peripheral Neuropathy stem cell therapy — your questions answered (2026)
- Peripheral Neuropathy: cell-therapy evidence by therapy class
- MSC vs PRP for Peripheral Neuropathy: what the registries show
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.